WO2026110120 - DOUBLE STRANDED RNAI AGENTS, COMPOSITIONS AND METHODS OF USE
National phase entry is expected:
Publication Number
WO/2026/110120
Publication Date
28.05.2026
International Application No.
PCT/IB2025/062014
International Filing Date
24.11.2025
Title **
[English]
DOUBLE STRANDED RNAI AGENTS, COMPOSITIONS AND METHODS OF USE
[French]
AGENTS ARNI DOUBLE BRIN, COMPOSITIONS ET PROCÉDÉS D'UTILISATION
Applicants **
NOVARTIS AG
Inventors
HUNZIKER, Juerg
Priority Data
63/724,676
25.11.2024
US
63/841,428
10.07.2025
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 6457 | |
| EPO | Filing, Examination, Granting | 95750 | |
| Japan | Filing, Examination, Granting | 4742 | |
| South Korea | Filing, Examination, Granting | 7383 | |
| USA | Filing, Examination, Granting | 33740 |
Total:
148,072
Contact Us
Abstract[English]
Disclosed are, inter alia, therapeutic dsRNAi agents with at least one TNA clamp on the sense strand for use in silencing a target gene in a cell or in a subject.[French]
La présente invention concerne, entre autres, des agents thérapeutiques de type ARNi double brin (ARNidb)comportant au moins une pince TNA sur le brin sens, destinés à être utilisés pour le silençage d'un gène cible dans une cellule ou chez un sujet.